Moderna, Inc. Stock price

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 27/02/2024 GMT 5-day change 1st Jan Change
96.2 USD +2.32% Intraday chart for Moderna, Inc. +10.59% -3.27%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2024 * 4.26B 336B Sales 2025 * 4.95B 390B Capitalization 35.92B 2,832B
Net income 2024 * -2.74B -216B Net income 2025 * -1.83B -145B EV / Sales 2024 * 7.36 x
Net cash position 2024 * 4.54B 358B Net cash position 2025 * 3.35B 264B EV / Sales 2025 * 6.58 x
P/E ratio 2024 *
-13.5 x
P/E ratio 2025 *
-19.4 x
Employees 5,600
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.18%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.32%
1 week+10.59%
Current month-4.80%
1 month-5.51%
3 months+23.78%
6 months-14.05%
Current year-3.27%
More quotes
1 week
91.06
Extreme 91.06
101.73
1 month
84.06
Extreme 84.06
105.81
Current year
84.06
Extreme 84.06
115.97
1 year
62.55
Extreme 62.55
163.24
3 years
62.55
Extreme 62.55
497.49
5 years
11.54
Extreme 11.54
497.49
10 years
11.54
Extreme 11.54
497.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 28/02/11
Director of Finance/CFO 47 05/09/22
President 48 31/12/12
Members of the board TitleAgeSince
Director/Board Member 65 31/05/18
Director/Board Member 74 30/06/20
Director/Board Member 67 10/12/19
More insiders
Date Price Change Volume
27/02/24 96.2 +2.32% 3,072,927
26/02/24 94.02 -2.53% 4,580,980
23/02/24 96.46 -3.00% 4,531,114
22/02/24 99.44 +13.53% 11,354,471
21/02/24 87.59 +0.69% 3,759,970

Delayed Quote Nasdaq, February 27, 2024 at 09:00 pm

More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
96.2 USD
Average target price
133.8 USD
Spread / Average Target
+39.05%
Consensus
  1. Stock
  2. Equities
  3. Stock Moderna, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW